Bhattacharjee Rudrarup, Das Roy Lopamudra, Choudhury Amarendranath
Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia.
Breast Cancer Hub, Concord, NC, 28027, USA.
Discov Oncol. 2022 Jun 8;13(1):45. doi: 10.1007/s12672-022-00509-x.
The research focus on CRISPR/Cas9 has gained substantial concentration since the discovery of 'an unusual repeat sequence' reported by Ishino et al. (J Bacteriol 169:5429-5433, 1987) and the journey comprises the recent Nobel Prize award (2020), conferred to Emmanuelle Charpentier and Jennifer Doudna. Cumulatively, the CRISPR has a short, compact, and most discussed success of its application in becoming one of the most versatile and paradigm shifting technologies of Biological Research. Today, the CRISPR/Cas9 genome editing system is almost ubiquitously utilized in many facets of biological research where its tremendous gene manipulation capability has been harnessed to create miracles. From 2012, the CRISPR/Cas 9 system has been showcased in almost 15,000 research articles in the PubMed database, till date. Backed by some strong molecular evidence, the CRISPR system has been utilized in a few clinical trials targeted towards various pathologies. While the area covered by CRISPR is cosmic, this review will focus mostly on the utilization of CRISPR/Cas9 technology in the field of cancer therapy.
自石野等人(《细菌学杂志》169:5429 - 5433, 1987)报道“一种不寻常的重复序列”以来,对CRISPR/Cas9的研究受到了广泛关注,这一历程还包括近期授予埃玛纽埃勒·沙尔庞捷和詹妮弗·杜德纳的诺贝尔奖(2020年)。总体而言,CRISPR在应用方面取得了短暂、紧凑且备受讨论的成功,成为生物研究中最通用且具有范式转变意义的技术之一。如今,CRISPR/Cas9基因组编辑系统几乎在生物研究的许多方面都有广泛应用,其强大的基因操纵能力被用于创造奇迹。截至目前,自2012年以来,CRISPR/Cas 9系统已在PubMed数据库中近15000篇研究文章中被提及。在一些有力的分子证据支持下,CRISPR系统已被用于针对各种病症的一些临床试验。虽然CRISPR涵盖的领域极为广泛,但本综述将主要聚焦于CRISPR/Cas9技术在癌症治疗领域的应用。